RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
23,71Â US$
arrow_upward
+1,45%(+0,34) 1K
23,71Â US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 21-may, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoRARE tikeri uchun statistika yaratilmoqda...
Ochish
23,42Â US$
Yuqori
24,12Â US$
Past
23,10Â US$
Bozor kapitali
2,34Â mlrd
Oʻrtacha hajm
1,70Â mln
Hajmi
1,27Â mln
52 haftalik eng yuqori
42,37Â US$
52 haftalik eng past
18,29Â US$
Aksiya boʻyicha daromad
-6,10Â US$
Beta
0,39
Muomaladagi aksiyalar
98,49Â mln
Xodimlar soni
1Â ming
Yangiliklar
Internetdagi manbalardan
Investing.com
·
16 soat oldin
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook
Investing.com Australia
·
19 soat oldin
Ultragenyx Pharmaceutical’s SWOT analysis: stock faces pivotal trial results By Investing.com
TipRanks
·
1 kun oldin
Ultragenyx Earnings Call Balances Growth and Cash Burn
TipRanks
·
2 kun oldin
Ultragenyx Stock Tumbles as Setbacks Rattle Investors
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Ultragenyx Pharmaceutical Inc haqida
CEOEmil Kakkis
Xodimlar soni1,37Â ming
Asos solingan2010
Bosh ofislarNovato, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytultragenyx.com
AI kontentda xatolar boʻlishi mumkin. Batafsil